Literature DB >> 21899664

The influence of prophylactic factor VIII in severe haemophilia A.

M Gissel1, M F Whelihan, L A Ferris, K G Mann, G E Rivard, K E Brummel-Ziedins.   

Abstract

Haemophilia A individuals displaying a similar genetic defect have heterogeneous clinical phenotypes. Our objective was to evaluate the underlying effect of exogenous factor (f)VIII on tissue factor (Tf)-initiated blood coagulation in severe haemophilia utilizing both empirical and computational models. We investigated twenty-five clinically severe haemophilia A patients. All individuals were on fVIII prophylaxis and had not received fVIII from 0.25 to 4 days prior to phlebotomy. Coagulation was initiated by the addition of Tf to contact-pathway inhibited whole blood ± an anti-fVIII antibody. Aliquots were quenched over 20 min and analyzed for thrombin generation and fibrin formation. Coagulation factor levels were obtained and used to computationally predict thrombin generation with fVIII set to either zero or its value at the time of the draw. As a result of prophylactic fVIII, at the time of the blood draw, the individuals had fVIII levels that ranged from <1% to 22%. Thrombin generation (maximum level and rate) in both empirical and computational systems increased as the level of fVIII increased. FXIII activation rates also increased as the fVIII level increased. Upon suppression of fVIII, thrombin generation became comparable in both systems. Plasma composition analysis showed a negative correlation between bleeding history and computational thrombin generation in the absence of fVIII. Residual prophylactic fVIII directly causes an increase in thrombin generation and fibrin cross-linking in individuals with clinically severe haemophilia A. The combination of each individual's coagulation factors (outside of fVIII) determine each individual's baseline thrombin potential and may affect bleeding risk.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21899664      PMCID: PMC3778653          DOI: 10.1111/j.1365-2516.2011.02638.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  27 in total

1.  Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis.

Authors:  G C White; F Rosendaal; L M Aledort; J M Lusher; C Rothschild; J Ingerslev
Journal:  Thromb Haemost       Date:  2001-03       Impact factor: 5.249

2.  The significance of circulating factor IXa in blood.

Authors:  Saulius Butenas; Thomas Orfeo; Matthew T Gissel; Kathleen E Brummel; Kenneth G Mann
Journal:  J Biol Chem       Date:  2004-03-23       Impact factor: 5.157

3.  Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.

Authors:  I M Nilsson; E Berntorp; T Löfqvist; H Pettersson
Journal:  J Intern Med       Date:  1992-07       Impact factor: 8.989

4.  A simple method for the preparation of homogeneous phospholipid vesicles.

Authors:  Y Barenholz; D Gibbes; B J Litman; J Goll; T E Thompson; R D Carlson
Journal:  Biochemistry       Date:  1977-06-14       Impact factor: 3.162

5.  Hageman factor fragment inhibitor in corn seeds: purification and characterization.

Authors:  Y Hojima; J V Pierce; J J Pisano
Journal:  Thromb Res       Date:  1980-10-15       Impact factor: 3.944

6.  Cooperative activation of human factor IX by the human extrinsic pathway of blood coagulation.

Authors:  J H Lawson; K G Mann
Journal:  J Biol Chem       Date:  1991-06-15       Impact factor: 5.157

7.  Factor XIII combined with recombinant factor VIIa: a new means of treating severe hemophilia A.

Authors:  C J Rea; J H Foley; J Ingerslev; B Sørensen
Journal:  J Thromb Haemost       Date:  2011-03       Impact factor: 5.824

8.  A model for the stoichiometric regulation of blood coagulation.

Authors:  Matthew F Hockin; Kenneth C Jones; Stephen J Everse; Kenneth G Mann
Journal:  J Biol Chem       Date:  2002-03-13       Impact factor: 5.157

9.  Thrombin functions during tissue factor-induced blood coagulation.

Authors:  Kathleen E Brummel; Sara G Paradis; Saulius Butenas; Kenneth G Mann
Journal:  Blood       Date:  2002-07-01       Impact factor: 22.113

10.  Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa.

Authors:  B Sørensen; J Ingerslev
Journal:  J Thromb Haemost       Date:  2004-01       Impact factor: 5.824

View more
  5 in total

Review 1.  Modeling thrombin generation: plasma composition based approach.

Authors:  Kathleen E Brummel-Ziedins; Stephen J Everse; Kenneth G Mann; Thomas Orfeo
Journal:  J Thromb Thrombolysis       Date:  2014-01       Impact factor: 2.300

Review 2.  Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives.

Authors:  Guy Young; Benny Sørensen; Yesim Dargaud; Claude Negrier; Kathleen Brummel-Ziedins; Nigel S Key
Journal:  Blood       Date:  2013-01-14       Impact factor: 22.113

3.  Evaluation of recombinant factor VIII Fc (Eloctate) activity by thromboelastometry in a multicenter phase 3 clinical trial and correlation with bleeding phenotype.

Authors:  Frank Driessler; Maricel G Miguelino; Glenn F Pierce; Robert T Peters; Jurg M Sommer
Journal:  Blood Coagul Fibrinolysis       Date:  2017-10       Impact factor: 1.276

4.  From principle to practice: bridging the gap in patient profiling.

Authors:  Jonathan H Foley; Thomas Orfeo; Anetta Undas; Kelley C McLean; Ira M Bernstein; Georges-Etienne Rivard; Kenneth G Mann; Stephen J Everse; Kathleen E Brummel-Ziedins
Journal:  PLoS One       Date:  2013-01-25       Impact factor: 3.240

5.  In silico thrombin generation: Plasma composition imbalance and mortality in human immunodeficiency virus.

Authors:  Kathleen E Brummel-Ziedins; Matthew Gissel; Jacqueline Neuhaus; Álvaro H Borges; David R Chadwick; Sean Emery; James D Neaton; Russell P Tracy; Jason V Baker
Journal:  Res Pract Thromb Haemost       Date:  2018-09-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.